Abstract：Objective: To explore the effects of dexmedetomidine on the proliferation, migration, and invasion of ovarian cancer cells by regulating Notch/JAG1 pathway. Methods: SKOV-3 cells were grouped into control group, low-dose dexmedetomidine group (1 nmoL/L), medium-dose dexmedetomidine group (10nmoL/L), a high-dose dexmedetomidine group (100nmoL/L), and high-dose dexmedetomidine+activator group (100nmol/L dexmedetomidine+8 mmoL/L propionic acid). The proliferation ability of cells was determined using MTT assay and Edu staining method. The apoptosis of cells was determined using TUNEL staining method. The migration ability of cells was determined using the cell scratch assay. The invasion ability of cells was determined using the Transwell method. The Ki67, Cyclin D1, Bcl-2, Notch1, and JAG1 proteins in each group were determined by Western blot. Results: Compared with the control group, the low, medium, and high dose dexmedetomidine groups showed a decrease in cell OD value, Edu positive cell rate, scratch migration rate, a reduction in cell invasion number, a clear decrease in Ki67, Cyclin D1, Bcl-2, Notch1, and JAG1 proteins, and a clear increase in cell apoptosis rate and Bax protein (P<0.05), which were dose-dependent (P<0.05). Compared with the high-dose dexmedetomidine group, the high-dose dexmedetomidine+activator group showed an increase in cell OD value, Edu positive cell rate, and scratch migration rate, an increase in cell invasion number, an increase in Ki67, Cyclin D1, Bcl-2, Notch1, and JAG1 proteins, and a decrease in cell apoptosis rate and Bax protein (P<0.05). Conclusion: Dexmedetomidine inhibits ovarian cancer cell proliferation, migration, and invasion by suppressing Notch/JAG1 pathway.
葛鑫, 袁蕾, 秦娇. 右美托咪定调节Notch/JAG1通路对卵巢癌细胞增殖迁移和侵袭的影响[J]. 河北医学, 2025, 31(9): 1465-1471.
GE Xin, YUAN Lei, QIN Jiao. Effects of Dexmedetomidine on the Proliferation Migration and Invasion of Ovarian Cancer Cells by Regulating Notch/JAG1 Pathway. HeBei Med, 2025, 31(9): 1465-1471.
[1] Yang L,Xie HJ,Li YY,et al.Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review)[J].Oncol Rep,2022,47(4):82. [2] Vorderbruggen M,Velazquez-Martinez CA,Natarajan A,et al.PROTACs in ovarian cancer:current advancements and future perspectives[J].Int Mol Sci,2024,25(10):5067. [3] Cai Q,Liu G,Huang L,et al.The role of dexmedetomidine in tumor-progressive factors in the perioperative period and cancer recurrence:a narrative review[J].Drug Des Devel Ther,2022,16(1):2161-2175. [4] Xiao X,Wang W,Guo C,et al.Hypermethylation leads to the loss of HOXA5,resulting in JAG1 expression and NOTCH signaling contributing to kidney fibrosis[J].Kidney Int,2024,106(1):98-114. [5] 周翼,王晓东,齐少霞,等.布托啡诺调节JAG1/Notch信号通路对乳腺癌细胞恶性生物学行为的影响[J].中国优生与遗传杂志,2023,31(10):2059-2065. [6] Choi SY,Choi JH.Ovarian cancer and the microbiome:connecting the dots for early diagnosis and therapeutic innovations-A review[J].Medicina (Kaunas),2024,60(3):516. [7] Zhao H,Xu Y,Shang H.Ferroptosis:a new promising target for ovarian cancer therapy[J].Int Med Sci,2022,19(13):1847-1855. [8] Waloejo CS,Musalim DAP,Budi DS,et al.Dexmedetomidine as an adjuvant to nerve block for cancer surgery:a systematic review and meta-analysis[J].Clin Med,2024,13(11):3166. [9] Tian H,Hou L,Xiong Y,et al.Effect of dexmedetomidine-mediated insulin-like growth factor 2 (IGF2) signal pathway on immune function and invasion and migration of cancer cells in rats with ovarian cancer[J].Med Sci Monit,2019,25(1):4655-4664. [10] Yu J,Zhu C,Wang X,et al.Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis[J].Sci Transl Med,2021,13(599):1692-1703. [11] Katoh M,Katoh M.Precision medicine for human cancers with notch signaling dysregulation (Review)[J].Int Mol Med,2020,45(2):279-297. [12] Qiao X,Ma B,Sun W,et al.JAG1 is associated with the prognosis and metastasis in breast cancer[J].Sci Rep,2022,12(1):21986.
2025, Vol. 31 
冀公网安备13080202000786号